Ascentage Pharma Group International
OTC: AAPGV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dajun Yang
- Employees
- 574
- Headquarters
- Suzhou, China
- IPO year
- 2025
- Market cap
- $127.3M
- Website
- https://www.ascentage.cn
Loading AAPGV…
Loading profile data…Frequently asked questions about AAPGV
What does Ascentage Pharma Group International (AAPGV) do?
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapeutic solutions for various cancers, chronic hepatitis B virus (HBV) infection, and age-related conditions, primarily within Mainland China. Its flagship product candidate, HQP1351, is a BCR-ABL inhibitor specifically designed to target BCR...
Where does AAPGV trade?
Ascentage Pharma Group International (AAPGV) trades on the Other OTC.
What sector is AAPGV in?
Ascentage Pharma Group International (AAPGV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ascentage Pharma Group International?
Dajun Yang is the chief executive officer of Ascentage Pharma Group International (AAPGV).
Where is Ascentage Pharma Group International headquartered?
Ascentage Pharma Group International is headquartered in China.
Does AAPGV pay a dividend?
Ascentage Pharma Group International (AAPGV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AAPGV go public?
Ascentage Pharma Group International (AAPGV) completed its initial public offering in 2025.